Michael Liang

Michael Liang oversees healthcare investments on the venture side of Baird Capital and has been with the firm since 2006. Prior to joining Baird Capital, Mike was a healthcare investor with Advent Venture Partners (London, UK) and before that served in an operating role as a Director of R&D at Cortek, a spinal orthopedics company. Mike currently serves on the Board of Directors of Apervita, AiCure, GreenLight Biosciences, Oncology Analytics, and Zurex Pharma. He was previously a board member of Veniti (sold to Boston Scientific) Interlace Medical (sold to Hologic) and a board observer of TomoTherapy (NASDAQ: TOMO). Mike received a B.S. from the University of California Berkeley in bioorganic chemistry, completed a Ph.D. in biophysical chemistry from Stanford University, and conducted a postdoctoral fellowship at Harvard University.